JPMorgan initiated coverage with an Overweight rating and a HK$95 target price, and with Stapokibart (CM310) product revenue up 227% year-on-year in the first three quarters, KEYMED BIO-B opened 0.9% lower, probed a low and rebounded, spiking to HK$74.45 at 09:56 BJ before fading through the afternoon to close at HK$73.00, up 5.3% from the prior close of HK$69.30 on HK$196 million turnover. Broad strength in innovative-drug names provided the backdrop; second-quarter revenue of HK$356 million rose 30.4% year-on-year and net profit of HK$703 million rose more than 17-fold, a 197% net margin, though operating loss remained at HK$111 million, 40.9% wider, indicating profit leans on non-operating items. The price sits below MA20 of 74.47 and MA60 of 76.33, 19.1% under the 52-week high of HK$89.75, up 35.8% year-to-date at a 24.35x P/E. Still, China Universal earlier cut 991,000 shares at about HK$70.9, leaving shareholder selling and sentiment after clinical data disclosures worth watching.